Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17489
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsao, Simon Chang-Hao-
dc.contributor.authorWang, Jing-
dc.contributor.authorWang, Yuling-
dc.contributor.authorBehren, Andreas-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorTrau, Matt-
dc.date2018-04-16-
dc.date.accessioned2018-04-22T23:56:47Z-
dc.date.available2018-04-22T23:56:47Z-
dc.date.issued2018-04-
dc.identifier.citationNature Communications 2018; 9(1): 1482-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/17489-
dc.description.abstractReal-time monitoring of cancer cells' phenotypic evolution during therapy can provide vital tumour biology information for treatment management. Circulating tumour cell (CTC) analysis has emerged as a useful monitoring tool, but its routine usage is restricted by either limited multiplexing capability or sensitivity. Here, we demonstrate the use of antibody-conjugated and Raman reporter-coated gold nanoparticles for simultaneous labelling and monitoring of multiple CTC surface markers (named as "cell signature"), without the need for isolating individual CTCs. We observe cell heterogeneity and phenotypic changes of melanoma cell lines during molecular targeted treatment. Furthermore, we follow the CTC signature changes of 10 stage-IV melanoma patients receiving immunological or molecular targeted therapies. Our technique maps the phenotypic evolution of patient CTCs sensitively and rapidly, and shows drug-resistant clones having different CTC signatures of potential clinical value. We believe our proposed method is of general interest in the CTC relevant research and translation fields.-
dc.language.isoeng-
dc.titleCharacterising the phenotypic evolution of circulating tumour cells during treatment.-
dc.typeJournal Article-
dc.identifier.journaltitleNature Communications-
dc.identifier.affiliationSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD, Australiaen
dc.identifier.affiliationDepartment of Molecular Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, Australiaen
dc.identifier.affiliationCentre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, QLD, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia .-
dc.identifier.doi10.1038/s41467-018-03725-8-
dc.identifier.orcid0000-0003-3627-7397-
dc.identifier.orcid0000-0001-5329-280X-
dc.identifier.pubmedid29662054-
dc.type.austinJournal Article-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.